Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good morning peeps
Insys Soars on Huge FDA Win
By Chris Lange July 5, 2016 8:40 am EDT
Insys Therapeutics Inc. (NASDAQ: INSY) shares made a leap early on Tuesday following a key U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has approved its dronabinol oral solution, Syndros, for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
At the same time, Insys also announced that Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration. The company expects to launch Syndros in the second half of 2016.
Advertisement
For some background: Syndros is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (THC).
Roughly 9,500 prescribers account for 70% of current dronabinol prescriptions. Insys expects to convert a large portion of the market to Syndros, as well as expand the market through direct detailing to physicians, highlighting the improved product profile of Syndros.
Dr. John N. Kapoor, chairman, CEO and president, commented:
We are very pleased to announce FDA approval of Syndros. We believe that Syndros will be an important new treatment option for patients suffering from the devastating effects of chemotherapy induced nausea and vomiting, as well as those fighting anorexia associated with weight loss in AIDS.
He added:
Syndros is the first and only FDA approved dronabinol solution for oral use. It is a liquid that is easy-to-swallow and allows for the dosage to be titrated to clinical effect. Once Syndros has been opened, it does not need to be refrigerated for 28 days. We believe that these product features coupled with patient support services will prove to be important differentiators for patients and prescribers and will be key drivers of a successful market launch and sustained growth. We expect that Syndros’ attractive profile will enable rapid market conversion and expansion, making for a significant long-term commercial opportunity for Insys.
I'm still holding but sure would like to see those financials and the Name Change. DEA could make a decision as early as this or next week and we are still listed as Wisdom Homes. Letting the world know we are an MJ company and not a home building Co. would bring immediate positive momentum. Lets have some news WOFA and get noticed. Right now I feel like I'm watching grass grow.
How many of you longs are just waiting and watching? Roll Call
I agree with you 2times2 exaggerated pumps as well as dumps do us no good, smart people do their own DD and know the truth on any stock. I have done mine or I would not be here holding 3/4 million shares, We just need more transparency form the company. Without the name change we are invisible to wall street and retail investors. I'm expecting some news soon, not going to see much movement until we are recognized as an MJ company. Also I know everyone is watching and waiting but a little more chatter on this board would be helpful to the general population of investors, new and old.
Good Morning people,any thoughts on what's going on with this stock?
Me to Jimmy, could have bought more at 0.05 and waited for a further dip that never happened. Needleless to say I'm kicking myself for not jumping in at .05 see what happens tomorrow.
Investor awareness is not going to happen until the Name change. It still looks like we are a home building company not an MJ stock. If anyone can obtain information from the company as to when this will happen, please post it here. Can't understand why it's taking so long this and other information to come forth. The company needs to be more transparent with the stockholders. Let's put a fire under their arse and get informed.
The Plant that Stops Antibiotic-Resistant Bacteria
“Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms emerge and spread globally every day, threatening our ability to treat common infectious diseases. A growing list of infections—such as pneumonia, tuberculosis, blood poisoning and gonorrhoea—are becoming harder, and sometimes impossible, to treat as antibiotics become less effective.”
“All five major cannabinoids (cannabidiol, cannabichromene, cannabigerol, ?9-tetrahydrocannabinol, and cannabinol) showed potent activity against a variety of methicillin-resistant Staphylococcus aureus (MRSA) strains of current clinical relevance.”
“All compounds showed potent antibacterial activity … Activity was exceptional against some of these strains..."
http://www.wakingtimes.com/2016/06/30/plant-stops-antibiotic-resistant-bacteria/
OK Darth Certain people deserve the extra respect and you are one of them. Keep up with the great post. GLTA
Hey Darth do you mind if I post some of your stuff on another site?
Volume over one million not bad for early morning trading, Name change will be like a shot of Vit-B12 for us, can't wait for it.
2times2 I wish 6 Million but happy with 600K for now holding and waiting to pounce on news.
Hey Wopper glad to see you back!
The Billions in revenue from legal MJ is the driving force here. The bottom line always wins out. The Feds and the states are chomping at the bit for al those Benjamin's.
Holding with 600000 shares, rally coming over the next few weeks and months. DEA schedule change, November elections, California legalizing Rec MJ gonna be big. Canna strips will have a perfect fit in the booming medical MJ industry.
Cannabis Oil (Cannabidiol CBD) without a prescription in all 50 United States.
This Review was created to expose the truth behind CBD oil
(Health Review) – If you haven’t already heard, Cannabidiol (CBD) is a non-psychoactive component of Cannabis that seems to have a wide range of therapeutic benefits. CBD is naturally occurring in the Hemp plant and according to the United States own government patent #6,630,507 “it supports the nutritional health of aging bodies. Cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.”
Some benefits scientists suggest people are getting from Cannabidiol (CBD)
•Reduced feelings of anxiety
•Reversing brain damage caused by alcohol
•Anti-inflammatory, neuro-protective, and anti-oxidant
We decided to see what expert medical doctors and product users had to say about Cannabidiol (CBD), and the results were surprising. In fact, Dr. Sanjay Gupta, a neurosurgeon, a medical professor and an Emmy award-winning chief medical correspondent for CNN concluded “…The science is there. This isn’t anecdotal. We have been terribly and systematically misled for nearly 70 years in the United States.”
For long term health and wellness use, CBD is one of the best ways to keep a body healthy. Studies suggest, for specific ailments, CBD may help in many ways.
Anxiety Pain/Chronic Pain
Inflammation Spasms
Sleep Disorders Rheumatoid Arthritis
Diabetes Alcoholism
MS Schizophrenia
PTSD Epilepsy
Neuro Disorders Parkinson’s
Cannabis Oil (Cannabidiol CBD)
This Review was created to expose the truth behind CBD oil
(Health Review) – If you haven’t already heard, Cannabidiol (CBD) is a non-psychoactive component of Cannabis that seems to have a wide range of therapeutic benefits. CBD is naturally occurring in the Hemp plant and according to the United States own government patent #6,630,507 “it supports the nutritional health of aging bodies. Cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.”
Some benefits scientists suggest people are getting from Cannabidiol (CBD)
•Reduced feelings of anxiety
•Reversing brain damage caused by alcohol
•Anti-inflammatory, neuro-protective, and anti-oxidant
We decided to see what expert medical doctors and product users had to say about Cannabidiol (CBD), and the results were surprising. In fact, Dr. Sanjay Gupta, a neurosurgeon, a medical professor and an Emmy award-winning chief medical correspondent for CNN concluded “…The science is there. This isn’t anecdotal. We have been terribly and systematically misled for nearly 70 years in the United States.”
For long term health and wellness use, CBD is one of the best ways to keep a body healthy. Studies suggest, for specific ailments, CBD may help in many ways.
Anxiety Pain/Chronic Pain
Inflammation Spasms
Sleep Disorders Rheumatoid Arthritis
Diabetes Alcoholism
MS Schizophrenia
PTSD Epilepsy
Neuro Disorders Parkinson’s
Edibles producers in Oregon are increasing production after a strong start to recreational marijuana sales earlier this month.
While recreational sales of flower began in Oregon last October, edibles, extracts and topicals were only allowed to be sold to adult-use customers starting June 2. A state economist predicted a 10%-15% recreational sales increase early in the month followed by a slowdown, the Statesman Journal reported.
But the economist said even though a sales boom isn’t necessarily expected, he still thinks sales will be solid because edible products typically aren’t available on the black market. And they’re very popular products.
Regardless, companies such as Gaia Bounty are ramping up production to meet demand on both the medical and rec side, a spokesman told the paper. The company specializes in infused chocolate bars.
All good news coming soon but no one knows who we are. Come on WOFA, change that name and let the investors know we are an MJ stock, so we can move on up. If any big news hits before the Name Change we're gonna miss the boat for the initial run. We have a great product for the medical end of MJ but where invisible to new money. GLTA
California gets go-ahead to vote on legalization of marijuana
June 28, 2016 11:04 PM
(Reuters) - Californians are set to decide whether to make recreational marijuana use legal, as other Western states have done, after the California Secretary of State's office said on Tuesday the issue could be put to voters in the November ballot.
The proposed so-called "Adult Use of Marijuana Act," which is supported by Lieutenant Governor Gavin Newsom among others, would allow people aged 21 and older to possess as much as an ounce of marijuana for private recreational use and permit personal cultivation of as many as six marijuana plants.
"Today marks a fresh start for California, as we prepare to replace the costly, harmful and ineffective system of prohibition with a safe, legal and responsible adult-use marijuana system that gets it right and completely pays for itself," initiative spokesman Jason Kinney said in a statement.
The measure would also establish a system to license, regulate and tax sales of marijuana, while allowing city governments to exercise local control over or disallow commercial distribution within their borders.
The initiative required just over 402,000 valid signatures to qualify for the ballot and exceeded that number on Tuesday, the Secretary of State's office said. Secretary Alex Padilla is slated to certify the initiative on June 30.
Opinion polls show attitudes have shifted more in favor of liberalized marijuana laws since California voters defeated a recreational cannabis initiative in 2010.
California led the way in legalizing marijuana for medical purposes in 1996, with 22 other states and the District of Columbia following suit, although cannabis remains classified as an illegal narcotic under U.S. law.
Voters in four states - Colorado, Washington, Oregon and Alaska - plus the District of Columbia, have gone a step further since 2012 in permitting recreational use for adults. Voters in several more states will consider similar legislation in November as well.
Opponents of liberalized marijuana laws have argued that such measures carry public safety risks and would make pot more accessible to youngsters.
A new survey out last week showed however that marijuana consumption by Colorado high school students has dipped slightly since the state first permitted recreational cannabis use by adults.
Medical Cannabis Company GW Pharma’s Stock Again Jumps
GW Pharmaceuticals – a publicly traded British medical cannabis company conducting clinical trials to determine how effective its medications are against epilepsy – watched its stock surge once again in response to a successful round of testing.
News Monday that a phase 3 trial was helpful at treating patients with Lennox-Gastaut Syndrome, a type of epilepsy, sent GW’s stock shooting up by more than 10% on the Nasdaq in morning trading, according to Business Insider. It closed up more than 6%.
Reuters reported the company’s stock had shot up by 21% during trading on the London Stock Exchange.
It’s the second time in recent months that GW Pharmaceuticals has seen its stock climb after news of a successful round of studies regarding epileptic treatments. The first was in March, when the company said it had successfully treated a number of children with Dravet’s Syndrome, another type of severe epilepsy, also with cannabis-derived medicine.
Both studies involved a product called Epidiolex, an MMJ spray.
GW is expecting to file for approval with the U.S. Food and Drug Administration by year’s end to get permission from the federal government for widespread production and distribution. That, however, would likely first require the Drug Enforcement Administration to reschedule cannabis, which is a possibility that may come to pass in the next month or so.
Medical Cannabis Company GW Pharma’s Stock Again Jumps
GW Pharmaceuticals – a publicly traded British medical cannabis company conducting clinical trials to determine how effective its medications are against epilepsy – watched its stock surge once again in response to a successful round of testing.
News Monday that a phase 3 trial was helpful at treating patients with Lennox-Gastaut Syndrome, a type of epilepsy, sent GW’s stock shooting up by more than 10% on the Nasdaq in morning trading, according to Business Insider. It closed up more than 6%.
Reuters reported the company’s stock had shot up by 21% during trading on the London Stock Exchange.
It’s the second time in recent months that GW Pharmaceuticals has seen its stock climb after news of a successful round of studies regarding epileptic treatments. The first was in March, when the company said it had successfully treated a number of children with Dravet’s Syndrome, another type of severe epilepsy, also with cannabis-derived medicine.
Both studies involved a product called Epidiolex, an MMJ spray.
GW is expecting to file for approval with the U.S. Food and Drug Administration by year’s end to get permission from the federal government for widespread production and distribution. That, however, would likely first require the Drug Enforcement Administration to reschedule cannabis, which is a possibility that may come to pass in the next month or so.
?
Marijuana Stigma Receding Among Some Big Companies
cannabis partnership
By Omar Sacirbey
The giants of American business are getting more comfortable about partnering with marijuana-related companies, and they’re willing to go public about it.
In the course of a week, news broke that software giant Microsoft Corp. and Arrow Electronics, a Fortune 150 company, had teamed with marijuana-related businesses.
It may be the tip of the iceberg, as Corporate America angles to grab a share of the growing marijuana industry. That could mean partnership opportunities for established cannabis companies, as well as mergers and acquisitions.
“I believe we are going to see many more mainstream companies brave enough to explore getting into the cannabis industry, especially over the next 30 days,” said Tom Quigley, CEO of The Gluu, an online B2B marketplace in Tampa, Florida, which serves marijuana companies.
Quigley believes the changing attitudes within Corporate America are not random. Rather, they’re connected in large part to widespread speculation that the Drug Enforcement Administration may soon remove marijuana from Schedule 1, the federal government’s classification for “the most dangerous drugs.”
That could have major ramifications for those in the industry, especially when it comes to medical research and perhaps taxes and banking.
“This is something that a lot of major companies are watching,” Quigley said. “They realize there could be a big change, and they want to be involved as soon as they can.”
The latest corporate giant to take the plunge is Colorado-based Arrow, which manufactures and distributes electronic components and devices. It is teaming with MyDx, a San Diego maker of handheld chemical analyzers that allow consumers to check the potency of marijuana strains.
In a news release, MyDx announced last week it had struck a deal with Arrow under which the Fortune 150 company will help manufacture MyDx’s analyzers and provide other services as well as a line of credit.
The previous week, Los Angeles-based Kind Financial announced it was partnering with Microsoft to offer seed-to-sale tracking systems to government customers to keep tabs on marijuana commerce.
Both of these partnerships come at a time when more than half the states have approved medical marijuana programs and a number of states are weighing recreational MJ this fall, opening the door to additional cannabis revenues nationwide.
Within the marijuana industry, meanwhile, the specter of large corporations entering the business has stoked fears that a small number of corporate players will corner the market and drive out the smaller, more established businesses. Whatever the case, the involvement of large companies would change the face of the industry.
Corporate Interest in Cannabis
Corporate interest in cannabis isn’t new. The marijuana industry had been piquing corporate interest long before the DEA announced in April it would make a decision about whether or not it would change marijuana’s Schedule I status.
For example, several marijuana-related businesses said such relationships have existed for years now in the form of cannabis-related companies buying materials or using online platforms from mainstream companies. Before Arrow, MyDx used another company to manufacture its device, but didn’t tout the relationship.
Arrow warranted publicity because of its size, said Daniel Yazbeck, MyDx’s CEO. Arrow initially will produce 10,000 of the company’s analyzers, but could make more if there is demand, Yazbeck said.
Although Arrow did not try to stop MyDx from touting their relationship, the company wasn’t eager to publicize it either, Yazbeck said. “They’re approaching this cautiously. They’re happy to work with us, but they’re not going to come out and be vocal about their involvement with cannabis.”
Arrow did not issue a statement about the partnership and did not return calls seeking comment.
Quigley, the B2B CEO, noted that for more than a year he has been meeting people who work at major financial institutions like JP Morgan and Salomon Smith Barney at industry conference after-parties and other industry get-togethers. These Wall Street types are interested in getting into the cannabis industry, he said.
An important difference, Quigley noted, is that a year ago or so ago these people were coming to cannabis conferences out of their own personal interest. More recently, however, he thinks executives at financial institutions have been sending staffers to cannabis industry events to do some corporate reconnaissance.
“In the past, it was independents who were trying to fish on their own. But now I think more people are being sent by their supervisors,” Quigley said. JP Morgan and Salomon Smith Barney could not be immediately reached for comment.
Cannaphobia Still Exists
To be sure, corporate cannaphobia has not vanished. Social media giants such as Facebook and Instagram have shuttered cannabis-related accounts, and banks and insurance companies are shunning marijuana clients. Still, Microsoft and Arrow’s participation in the cannabis industry suggests that marijuana isn’t the radioactive subject it was only a few years ago.
“There is some movement on the stigma,” said Jeanne Sullivan, founder of Sullivan Adventures, a New York investment advisory firm following the cannabis industry. “The enlightened companies know how to seek the best-of-breed companies that are being built and formed today, opening the door for partnership, scale, revenue opportunities and (merger and acquisition) activity.”
She added: “Arrow’s home base is Colorado, so they know up close the economic opportunities that the cannabis industry is able to generate.”
While the MyDx-Arrow partnership symbolizes promise for the cannabis industry, it’s also good for MyDx.
Under the agreement, Arrow will manage MyDx’s supply chain, manufacture MyDx’s line of chemical analyzers, and provide the company credit that it can use for its products.
“It’s great for MyDx because they have a partner who can help them improve the quality of their devices, and scale up manufacturing for them,” said Quigley. “When you’re a small company and want to move to the next level, this is the kind of move you want to make.”
Sullivan believes that Microsoft and Arrow have broken new ground that will unleash more interest in the cannabis industry among mainstream businesses.
“These types of partnerships highlight the opportunities now and ahead for entrepreneurial companies serving the cannabis sector,” she said.
Omar Sacirbey can be reached at omars@mjbizmedia.com
Daily News | Ancillary Marijuana Companies | Featured
June 28, 2016
Senators Put Pressure on DEA to Reschedule Marijuana
Marijuana Stigma Receding Among Some Big Companies
cannabis partnership
By Omar Sacirbey
The giants of American business are getting more comfortable about partnering with marijuana-related companies, and they’re willing to go public about it.
In the course of a week, news broke that software giant Microsoft Corp. and Arrow Electronics, a Fortune 150 company, had teamed with marijuana-related businesses.
It may be the tip of the iceberg, as Corporate America angles to grab a share of the growing marijuana industry. That could mean partnership opportunities for established cannabis companies, as well as mergers and acquisitions.
“I believe we are going to see many more mainstream companies brave enough to explore getting into the cannabis industry, especially over the next 30 days,” said Tom Quigley, CEO of The Gluu, an online B2B marketplace in Tampa, Florida, which serves marijuana companies.
Quigley believes the changing attitudes within Corporate America are not random. Rather, they’re connected in large part to widespread speculation that the Drug Enforcement Administration may soon remove marijuana from Schedule 1, the federal government’s classification for “the most dangerous drugs.”
That could have major ramifications for those in the industry, especially when it comes to medical research and perhaps taxes and banking.
“This is something that a lot of major companies are watching,” Quigley said. “They realize there could be a big change, and they want to be involved as soon as they can.”
The latest corporate giant to take the plunge is Colorado-based Arrow, which manufactures and distributes electronic components and devices. It is teaming with MyDx, a San Diego maker of handheld chemical analyzers that allow consumers to check the potency of marijuana strains.
In a news release, MyDx announced last week it had struck a deal with Arrow under which the Fortune 150 company will help manufacture MyDx’s analyzers and provide other services as well as a line of credit.
The previous week, Los Angeles-based Kind Financial announced it was partnering with Microsoft to offer seed-to-sale tracking systems to government customers to keep tabs on marijuana commerce.
Both of these partnerships come at a time when more than half the states have approved medical marijuana programs and a number of states are weighing recreational MJ this fall, opening the door to additional cannabis revenues nationwide.
Within the marijuana industry, meanwhile, the specter of large corporations entering the business has stoked fears that a small number of corporate players will corner the market and drive out the smaller, more established businesses. Whatever the case, the involvement of large companies would change the face of the industry.
Corporate Interest in Cannabis
Corporate interest in cannabis isn’t new. The marijuana industry had been piquing corporate interest long before the DEA announced in April it would make a decision about whether or not it would change marijuana’s Schedule I status.
For example, several marijuana-related businesses said such relationships have existed for years now in the form of cannabis-related companies buying materials or using online platforms from mainstream companies. Before Arrow, MyDx used another company to manufacture its device, but didn’t tout the relationship.
Arrow warranted publicity because of its size, said Daniel Yazbeck, MyDx’s CEO. Arrow initially will produce 10,000 of the company’s analyzers, but could make more if there is demand, Yazbeck said.
Although Arrow did not try to stop MyDx from touting their relationship, the company wasn’t eager to publicize it either, Yazbeck said. “They’re approaching this cautiously. They’re happy to work with us, but they’re not going to come out and be vocal about their involvement with cannabis.”
Arrow did not issue a statement about the partnership and did not return calls seeking comment.
Quigley, the B2B CEO, noted that for more than a year he has been meeting people who work at major financial institutions like JP Morgan and Salomon Smith Barney at industry conference after-parties and other industry get-togethers. These Wall Street types are interested in getting into the cannabis industry, he said.
An important difference, Quigley noted, is that a year ago or so ago these people were coming to cannabis conferences out of their own personal interest. More recently, however, he thinks executives at financial institutions have been sending staffers to cannabis industry events to do some corporate reconnaissance.
“In the past, it was independents who were trying to fish on their own. But now I think more people are being sent by their supervisors,” Quigley said. JP Morgan and Salomon Smith Barney could not be immediately reached for comment.
Cannaphobia Still Exists
To be sure, corporate cannaphobia has not vanished. Social media giants such as Facebook and Instagram have shuttered cannabis-related accounts, and banks and insurance companies are shunning marijuana clients. Still, Microsoft and Arrow’s participation in the cannabis industry suggests that marijuana isn’t the radioactive subject it was only a few years ago.
“There is some movement on the stigma,” said Jeanne Sullivan, founder of Sullivan Adventures, a New York investment advisory firm following the cannabis industry. “The enlightened companies know how to seek the best-of-breed companies that are being built and formed today, opening the door for partnership, scale, revenue opportunities and (merger and acquisition) activity.”
She added: “Arrow’s home base is Colorado, so they know up close the economic opportunities that the cannabis industry is able to generate.”
While the MyDx-Arrow partnership symbolizes promise for the cannabis industry, it’s also good for MyDx.
Under the agreement, Arrow will manage MyDx’s supply chain, manufacture MyDx’s line of chemical analyzers, and provide the company credit that it can use for its products.
“It’s great for MyDx because they have a partner who can help them improve the quality of their devices, and scale up manufacturing for them,” said Quigley. “When you’re a small company and want to move to the next level, this is the kind of move you want to make.”
Sullivan believes that Microsoft and Arrow have broken new ground that will unleash more interest in the cannabis industry among mainstream businesses.
“These types of partnerships highlight the opportunities now and ahead for entrepreneurial companies serving the cannabis sector,” she said.
June 28, 2016
Senators Put Pressure on DEA to Reschedule Marijuana
%%%%% Hello Is It Me Your Looking For %%%%%
%%%% Lonely I'm Mr. Lonely %%%%%
%%%% Help Me If You Can I'm Felling Down-oun %%%%
AS you can see I'm getting very bored on this board LOL
US Federal Government Is Thwarting MJ research
Marijuana is still categorized as more dangerous than cocaine, methamphetamine, and PCP.
Marijuana continues to gain its status as an effective treatment for a number of health conditions, from epilepsy to the severe pain experienced by chronic cancer patients. As of today, 23 states, as well as the District of Columbia and Puerto Rico, have legalized Cannabis sativa to benefit people suffering from a number of medical conditions.
In fact, a recent poll conducted by the New England Journal of Medicine reveals that the majority of physicians in the US — over 75 percent — believe that medical cannabis is a safe and effective treatment for a range of mental and physical health conditions.
However, according to a new paper published in Science, the federal government may be hindering researchers’ abilities to conduct proper research on the risks and benefits of medical marijuana.
"Millions of patients have been granted the authorization to use medical Cannabis and Cannabis-based products by their respective state Health Departments and four states have begun taxing and regulating Cannabis sold for 'recreational' purposes," study researchers Jacob Vigil and Sarah Stith, of the University of New Mexico, said in a press release.
"However, the federal government continues to categorize Cannabis sativa as a Schedule I drug under the Controlled Substances Act, a more restrictive categorization than that used for cocaine, methamphetamine and PCP."
Since marijuana is defined as a Schedule I drug, this means it’s labeled with a “high potential for abuse” and “no currently accepted medical use,” which is counterintuitive as it’s already legalized for medicinal purposes in a number of states.
Further, researchers are required to obtain research marijuana from the National Institute on Drug Abuse (NIDA), but the organization’s cannabis is far less potent than the cannabis products that are sold and used.
To put it in perspective, the highest level of THC available through NIDA is 12.4 percent, but the American Chemical Society found that the Cannabis sativa sold in Colorado averaged at 18.7 percent, with some strains as high as 35 percent. In New Mexico, some THC products even contain potency levels of 70 percent.
Plus, of the only two clinical studies funded by the National Institute of Health (NIH) last year, the products obtained from the University of Mississippi had THC potency levels between 3.5 and 7 percent — it goes without saying that such a variation in potency levels will produce results with a skewed picture of marijuana’s risks and benefits.
"Clearly, results from studies using Cannabis sativa obtained from the University of Mississippi offer little to no insight into the effects actually experienced by medical marijuana patients in terms of both therapeutic benefits and negative side effects, if any," Vigil and Stith said.
According to the researchers, the federal barriers to cannabis research have created an “unnecessary paradox in modern medicine,” as physicians are prescribing patients medicine “without a scientific basis of knowledge” about the potential risks and outcomes associated with medical cannabis.
"Unfortunately, both the costs and benefits of medicinal use of Cannabis sativa remain essentially unknown, and because the federal government effectively bans clinical research on Cannabis sativa, citizens, including many severely ill individuals, may suffer and die unnecessarily from both the unknown risks and the unknown benefits of consuming Cannabis sativa," the researchers conclude.
Glad to hear some chatter on the board, I realize there's not much happening right now but it's nice to hear what ever you longs have to say. I'm certain none of you sold any shares, your all to smart for that, just watching and waiting. Payday coming soon... GLTA
I'm locked and loaded 2times2, just waiting for the "News".
Name change, DEA ruling MJ off Schedule 1, California legalizing Rec use of MJ, more conclusive medical studies, November Elections etc. These are all positive catalyst that will be a boom for WOFA and the whole MJ sector. I wish all the longs here the very best of luck for there patience and investments. It will pay off, I have no doubt about that.
I'm glad somebody else posted I thought I fell into a black hole LOL News, News, News anyone have some?
Well I guess I have been talking to myself today. Where the hell is everybody?
Fortune 150 Company Partners With Ancillary Cannabis Firm
MyDx, a maker of handheld chemical analyzers that allow consumers to check the potency of marijuana strains, has struck a deal with Arrow Electronics, a Fortune 150 company, under which Arrow will help manufacture the analyzers and provide other services and credit for San Diego-based MyDx.
The agreement is the latest to emerge involving a marijuana-related company and a major corporation. Software giant Microsoft Corp. last week disclosed it’s teaming up with an established ancillary cannabis firm, Kind Financial, to land government technology contracts tied to the cannabis sector.
In a press release, MyDx said Colorado-based Arrow will manage its supply chain, provide manufacturing support for its line of consumer-oriented analyzers, offer technical support, and extend a line of credit. MyDx, which was founded in 2013, didn’t disclose the size of the credit facility.
In addition to cannabis, the company’s battery-operated analyzers allow consumers and others to test the organic properties of food, water and air.
MyDx’s CannaDX sensor, in particular, can be used to test cannabis flower for THC and CBD percentages as well as more than 20 terpenes.
The company said the data generated by the analyzer will provide “you with an accurate prediction of how this cannabis will make you feel and what symptoms it can potentially alleviate.”
Fortune 150 Company Partners With Ancillary Cannabis Firm
MyDx, a maker of handheld chemical analyzers that allow consumers to check the potency of marijuana strains, has struck a deal with Arrow Electronics, a Fortune 150 company, under which Arrow will help manufacture the analyzers and provide other services and credit for San Diego-based MyDx.
The agreement is the latest to emerge involving a marijuana-related company and a major corporation. Software giant Microsoft Corp. last week disclosed it’s teaming up with an established ancillary cannabis firm, Kind Financial, to land government technology contracts tied to the cannabis sector.
In a press release, MyDx said Colorado-based Arrow will manage its supply chain, provide manufacturing support for its line of consumer-oriented analyzers, offer technical support, and extend a line of credit. MyDx, which was founded in 2013, didn’t disclose the size of the credit facility.
In addition to cannabis, the company’s battery-operated analyzers allow consumers and others to test the organic properties of food, water and air.
MyDx’s CannaDX sensor, in particular, can be used to test cannabis flower for THC and CBD percentages as well as more than 20 terpenes.
The company said the data generated by the analyzer will provide “you with an accurate prediction of how this cannabis will make you feel and what symptoms it can potentially alleviate.”
Chart of the Week: Monthly Recreational Marijuana Sales in U.S. Averaging $124M
Chart on recreational marijuana
By Eli McVey
Colorado, Oregon and Washington State are averaging a combined $123.5 million in monthly recreational marijuana sales so far this year, putting the industry on pace to rack up at least $1.5 billion in adult-use cannabis revenue at the retail level in 2016.
The three states have all seen sizable monthly increases in recreational marijuana sales, underscoring the continued growth potential for this side of the cannabis industry.
If sales continue to grow on a monthly basis at current rates in these states, overall adult-use revenues could hit $1.8 billion or possibly even touch $2 billion this year. Alaska also is expected to get its recreational industry up and running in the second half of 2016, which will push the final tally even higher.
Monthly sales of recreational marijuana in the nation’s largest and oldest adult-use market, Colorado, averaged $62 million from January through April (the state has not yet released May data). Month-to-month growth has been somewhat uneven, but it averages out to a robust 7%.
Colorado’s rec industry hit a record in April, when sales totaled $76.6 million largely due to the 4/20 holiday.
In Washington State, recreational marijuana sales from January to May totaled $229 million, equating to a monthly average of $46 million. The state got off to an extremely slow start and lagged severely behind Colorado for a while, but it has made up some ground as of late.
Sales have grown about 5% a month so far this year in Washington, setting new records for the state in each of the past five months.
With Washington’s move to eliminate all medical marijuana dispensaries by July 1, 2016, the recreational industry could see a huge influx of new customers, meaning sales could rocket.
Oregon is the newest player on the market, having started rec sales through existing dispensaries last October.
During the first five months of the year, roughly $60 million worth of recreational marijuana was sold in the state, according to sales tax data released last week.
Oregon’s recreational market is still taking shape, as the first retail stores licensed specifically to sell recreational marijuana will open later this year. Dispensaries are limited in how much recreational marijuana they can sell now, and the state only just recently allowed them to provide the adult-use market with edibles.
Sales will therefore likely grow significantly each month going forward.
Chart of the Week: Monthly Recreational Marijuana Sales in U.S. Averaging $124M
Chart on recreational marijuana
By Eli McVey
Colorado, Oregon and Washington State are averaging a combined $123.5 million in monthly recreational marijuana sales so far this year, putting the industry on pace to rack up at least $1.5 billion in adult-use cannabis revenue at the retail level in 2016.
The three states have all seen sizable monthly increases in recreational marijuana sales, underscoring the continued growth potential for this side of the cannabis industry.
If sales continue to grow on a monthly basis at current rates in these states, overall adult-use revenues could hit $1.8 billion or possibly even touch $2 billion this year. Alaska also is expected to get its recreational industry up and running in the second half of 2016, which will push the final tally even higher.
Monthly sales of recreational marijuana in the nation’s largest and oldest adult-use market, Colorado, averaged $62 million from January through April (the state has not yet released May data). Month-to-month growth has been somewhat uneven, but it averages out to a robust 7%.
Colorado’s rec industry hit a record in April, when sales totaled $76.6 million largely due to the 4/20 holiday.
In Washington State, recreational marijuana sales from January to May totaled $229 million, equating to a monthly average of $46 million. The state got off to an extremely slow start and lagged severely behind Colorado for a while, but it has made up some ground as of late.
Sales have grown about 5% a month so far this year in Washington, setting new records for the state in each of the past five months.
With Washington’s move to eliminate all medical marijuana dispensaries by July 1, 2016, the recreational industry could see a huge influx of new customers, meaning sales could rocket.
Oregon is the newest player on the market, having started rec sales through existing dispensaries last October.
During the first five months of the year, roughly $60 million worth of recreational marijuana was sold in the state, according to sales tax data released last week.
Oregon’s recreational market is still taking shape, as the first retail stores licensed specifically to sell recreational marijuana will open later this year. Dispensaries are limited in how much recreational marijuana they can sell now, and the state only just recently allowed them to provide the adult-use market with edibles.
Sales will therefore likely grow significantly each month going forward.
More Top News
June 27, 2016
Firm’s Findings Show Promising Results Among Testing Labs
June 27, 2016
American Cannabis Co. Secures $5M Equity Stake
June 24, 2016
Former Cyclist Floyd Landis Launches Cannabis Company
June 24, 2016
Fortune 150 Company Partners With Ancillary Cannabis Firm
June 24, 2016
Medical Cannabis Legalization Blocked in Mexico
June 24, 2016
Top Marijuana Exec Denied Life Insurance
7 Reasons to Invest in Marijuana Stocks Now
By Cameron Saucier, Associate Editor, Money Morning • June 27, 2016
marijuana stocksMany investors wouldn't even consider adding marijuana stocks to their portfolio. They think most pot companies are scams or that the companies aren't capable of turning a profit.
But what used to be a limited opportunity in this market has turned into staggering money-making potential…
Regardless of your views on marijuana use, we are committed to helping you profit.
And simply put, pot stock investments are going to be a huge profit-generator.
Marijuana stocks are about to have a major breakthrough. In fact, there are seven reasons why the best "pot stocks" can deliver market-beating gains to investors over the next decade.
Best of all, most investors still haven't caught on to these reasons. That's why Money Morning is bringing them to your attention now, so you can be ahead of the curve – before the marijuana industry really takes off.
Check out our seven reasons to invest in marijuana stocks in 2016…
Reason No. 1 to Invest in Marijuana Stocks: Government Shift Toward Legalization
On Aug. 1, the U.S. Drug Enforcement Administration (DEA) could reclassify marijuana as a Schedule II drug, which would make it legal in all 50 states with a prescription, according to the Santa Monica Observer. A reporter from the newspaper questioned a DEA lawyer about the DEA's alleged plans to legalize marijuana. On the condition of anonymity, the DEA lawyer confirmed the allegations.
If this turns out to be true, Schedule II marijuana could be a huge catalyst for marijuana stocks.
Even if the change doesn't take place, marijuana use is still becoming more and more acceptable in the United States every year.
In fact, the rate of states legalizing marijuana has been soaring since 2000. Before 2000, only three states – California, Oregon, and Maine – had fully legalized medical cannabis.
But within the past six years, 15 states have legalized medical marijuana. That brings the total number of states where marijuana use is legal in some form to 25, including the District of Columbia.
In this year alone, two states – Pennsylvania and Ohio – have joined that growing list.
And the rate of states legalizing cannabis could increase even more in 2016…
There's a big vote coming up in November that could legalize some use of marijuana in more than 20 states. According to Ballotpedia, activists are submitting ballot measures for a public vote on marijuana legalization in each of these states:
?Arkansas, Arizona, California, Florida, Georgia, Idaho, Maine, Massachusetts, Michigan, Mississippi, Missouri, Montana, New Mexico, Ohio, North Dakota, Oklahoma, South Dakota, Utah, Wyoming, and Washington.
Reason No. 2 to Invest in Marijuana Stocks: Governments Will Say Yes to More Revenue
If there's anything governments love, it's more tax revenue. And that's what legal marijuana sales give them.
Just look at what happened in Washington and Colorado in 2014. Each state has legalized recreational marijuana use and collected around $70 million in tax revenue from marijuana sales, Time Magazine and CNN reported. That's about twice as much revenue as Colorado generated from alcohol taxes, according to analysts from the ArcView Group, a marijuana research firm. In 2015-2016, Colorado is expected to bring in $135 million in cannabis taxes.
marijuana industry
The U.S. marijuana market could be worth $30 billion annually by 2020, according to a 2015 report from the Bank of America Merrill Lynch, the first of such from any major financial institution. That's three times the yearly revenue of the National Football League, at $10 billion, The Washington Post reported.
Reason No. 3 to Invest in Marijuana Stocks: It's the Fastest-Growing Industry
The pot industry is growing rapidly. Analysts from the ArcView Group found that the marijuana industry grew 24% in 2015 to $5.7 billion. That makes legal marijuana one of the fastest-growing industries in the United States, according to ArcView. And in 2014, it was the fastest, according to the Bank of America Merrill Lynch report.
This year, the size of the legal marijuana market in the United States is expected to grow by $7.1 billion, according to ArcView. That represents 26% growth from 2015.
Reason No. 4 to Invest in Marijuana Stocks: Widespread Medical Use
There is a ton of research going into the medical applications of cannabis other than its traditional use as a painkiller.
Early research suggests cannabis can treat a large range of diseases and illnesses, such as schizophrenia, Type 2 diabetes, post-traumatic stress disorder, and even some types of cancer. Many existing cannabis-derived drugs on the market are already approved in countries such as the UK, Germany, and Spain. As more research is done in the United States, new cannabis drugs could even become approved by the U.S. Food and Drug Administration, according to the Bank of America report.
Currently, 25 states and the District of Colombia allow the use of marijuana for medical reasons. So far, though, not much FDA peer-reviewed research has been done on the medical applications of marijuana. One nonprofit, however, called the Multidisciplinary Association for Psychedelic Studies is trying to get marijuana approved by the FDA for the treatment of post-traumatic stress disorder.
A 2010 poll from ABC News showed that 81% of Americans believed that medical marijuana should be completely legal in the United States.
Reason No. 5 to Invest in Marijuana Stocks: The Growth in Investment Options
There are over 80 marijuana stocks that either trade over-the-counter or on the Nasdaq. So there are plenty of stocks out there to choose from. And as the marijuana industry grows, expect many more marijuana companies to go public.
Currently, the majority of these stocks are penny stocks, which trade for under $5.
Reason No. 6 to Invest in Marijuana Stocks: Banks Will Service the Business
On June 16, the U.S. Senate Appropriations Committee approved an addition to the Financial Services and General Government Appropriations bill that makes it easier for banks to provide services for legal marijuana businesses.
Currently, marijuana companies can only operate in cash, because most banks were afraid of doing business with them. But with the new measure, financial institutions would no longer fear opening up accounts for state-legal businesses.
For the bill to become law, it will need to be passed by the entire Senate and the House of Representatives. Then it would need the approval of the president.
Reason No. 7 to Invest in Marijuana Stocks: The Rise of Subsectors
Many people think that the marijuana industry is solely businesses that sell pot. But that's far from true. Some grow marijuana, while others make apps for pot sellers and users. Some even sell tools and equipment to help people grow and cultivate marijuana.
One of the sectors that will benefit most if marijuana is legalized federally is the biotech space, according to U.S. News & World Report. Current laws make marijuana research difficult, but legalization would allow biotech companies to research marijuana without fear of legal repercussions. Other areas that would benefit are the health and wellness, real estate, and software industries, according to the U.S. News & World Report.
The marijuana industry's wide breadth gives investors a lot options about where to put their money. And because it dips in all sorts of sectors, from tech to agriculture, the pot industry has plenty of room for future growth.
www.wtae.com/news/perception-vs-reality-dr-sanjay-gupta-on-medical-marijuana-research/40209756
This company better start moving on that name change and some PR, nobody knows who we are, look at that anemic volume. Buy the way where did everybody on this board go, let's see some life. Big things will be happening soon, we need investors to know that we are a MJ company not a housing co.
Anyone have news concerning WOFA Name Change or PR. DEA making decision soon, maybe this week on MJ rescheduling and legalization of MJ. GLTA
They took the old website down because the new one is coming soon probably next week.